Spruce Biosciences (NASDAQ:SPRB) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Spruce Biosciences (NASDAQ:SPRB) from a market perform rating to an outperform rating in a report published on Tuesday morning, MarketBeat reports. Citizens Jmp currently has $254.00 price target on the stock.

A number of other research firms also recently commented on SPRB. JMP Securities set a $254.00 price objective on shares of Spruce Biosciences and gave the stock a “market outperform” rating in a research note on Tuesday. Zacks Research lowered Spruce Biosciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 23rd. Citigroup raised Spruce Biosciences to an “outperform” rating in a research report on Tuesday. Leerink Partners set a $160.00 price target on Spruce Biosciences and gave the company a “market perform” rating in a research note on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spruce Biosciences in a research report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $176.38.

Spruce Biosciences Stock Down 9.1%

Shares of SPRB stock opened at $107.25 on Tuesday. Spruce Biosciences has a 12 month low of $4.28 and a 12 month high of $240.00. The company’s fifty day simple moving average is $61.03 and its 200-day simple moving average is $26.04. The firm has a market cap of $60.06 million, a PE ratio of -1.24 and a beta of 2.47.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.